about
National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and LinksVertical transmission rates for HIV in the British Isles: estimates based on surveillance data.Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimensCauses of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective surveyPneumocystis carinii pneumonia in vertically acquired HIV infection in the British Isles.Interventions to reduce mother-to-child transmission of HIV infection: new developments and current controversies.Economic issues in the prevention of vertical transmission of HIV.Early antiretroviral therapy improves neurodevelopmental outcomes in infantsImpact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in ZambiaPaediatric HIV infection--diagnostic and epidemiological aspects.A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteriaExploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial.Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.Risk of triple-class virological failure in children with HIV: a retrospective cohort studyFirst-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.Anaemia and blood transfusion in African children presenting to hospital with severe febrile illness.Advances in the prevention and treatment of paediatric HIV infection in the United KingdomA primary care level algorithm for identifying HIV-infected adolescents in populations at high risk through mother-to-child transmission.Pubertal development in HIV-infected African children on first-line antiretroviral therapy.Vertically transmitted HIV infection in the British Isles.Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis.Malignancies in UK children with HIV infection acquired from mother to child transmissionA family clinic--optimising care for HIV infected children and their families.Predicting mortality in sick African children: the FEAST Paediatric Emergency Triage (PET) Score.Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda.Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.HIV drug resistance testing: is the evidence really there?HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trialAbacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.Descriptive survey of antenatal HIV testing in London: policy, uptake, and detectionPlasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenPharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations.The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenDecline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland.Factors affecting uptake of antenatal HIV testing in London: results of a multicentre study.Considerations in the design of randomized controlled trials evaluating the optimal time to initiate antiretroviral therapy in previously untreated HIV-1-infected patients.Treatment interruption in children with HIV infection.Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
P50
Q30501533-0A6F3C87-B48B-46EC-98EE-767DC80A3CE0Q30583689-BA4078E1-E729-4025-A94E-5D377856E553Q33361748-47F91D88-5B91-4C6F-94C7-D46E8A324B2FQ33528970-671B44F1-2B49-4862-83C3-79B564FE2971Q33624462-5FEECC4E-44A3-4745-B550-0B90F3C188CFQ33961598-800F43D0-C8D8-4019-A51E-E397F1C6BAAFQ34048585-B8F1D5D4-FC99-471A-A16D-5D2A2EF42AF2Q34093261-1C4C6312-46AA-4B7B-88E5-2655915152CFQ34108680-D8ED9E17-9EDC-4184-9775-C91DB2C9A408Q34342861-552010E6-85BB-451C-9D13-426D34818C9FQ34600621-64BE946E-B7BE-4EB4-902A-2C68996376E6Q34621758-2EA0B9AB-A619-4D4B-A941-6F5577E9AF28Q34622948-A489D6DD-1A4A-4C9C-8558-C142E9F4A924Q34997180-8E6C990A-E423-4990-B3E6-FBB9EC7C9A0BQ35034306-AAD6B962-1CE4-435B-B52E-8004C5547167Q35036793-7FADC735-30BE-4D93-BA29-0350BADF328BQ35063310-C5A5556E-CF21-4267-BC28-3FE00C437937Q35094139-214E24FA-0F5B-4288-A6D7-0EA5FDE9CA79Q35126455-6F874A4E-5418-4C6E-A5A6-205A436DC39EQ35188006-A9EF0414-836A-43F2-8E96-6A1BD3843CD7Q35246507-CBE79BD1-512D-4A47-AC3A-C29B63F06C23Q35254904-DBD39C97-12F3-4A71-B743-447EAE3685D4Q35257807-FAFB04D5-5173-43E6-AF32-7EDDE4E1C312Q35728326-5298626C-7762-4137-9033-8A4E123FF8E5Q35854936-178582D2-E436-406B-8772-2D7D14967886Q35929985-E7365386-271C-4A5A-8639-D578E86B9C84Q35944396-894D579F-6DFE-47A3-B4BC-D030F97C8548Q36015636-2E5B49EB-95A7-42F8-9013-3BFA661760DCQ36416849-7F5954AF-84A8-491C-8964-7C3C99CDB89CQ36501872-48263C74-7563-4370-9893-87AEAFA0BD68Q36542643-B6CF4F0C-297D-4E01-A849-E5B199962A18Q36600027-2528FD21-39E9-42A6-A230-AD787540611AQ36683440-A31DFB21-E8D0-45C7-9764-BFD50927F91CQ36909252-7C0184AC-0AED-4248-B1C7-9BF1CBCF20F1Q37030715-9642CA38-F553-46D0-A380-D911AADA272CQ37043665-9730F5B3-63DA-497D-B8F1-BCAA113B22C8Q37150219-B24E3A25-0B5C-4DF0-AC00-4AA245B99717Q37447082-E6F17D35-E26D-4ACB-809D-4986F3919F80Q37447156-3BA74D40-8C4A-4491-972E-E07227582D2AQ37491278-A65652D7-A85E-4A86-A920-AD75D336E73B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Diana M Gibb
@ast
Diana M Gibb
@en
Diana M Gibb
@es
Diana M Gibb
@nl
type
label
Diana M Gibb
@ast
Diana M Gibb
@en
Diana M Gibb
@es
Diana M Gibb
@nl
prefLabel
Diana M Gibb
@ast
Diana M Gibb
@en
Diana M Gibb
@es
Diana M Gibb
@nl
P108
P106
P21
P31
P496
0000-0002-9738-5490